12 papers · ranked by Valyu relevance
Yuan Hong, Yingcai Feng, Hanzi Sun, Bo Zhang + 11 more
'Yucheng Li' 'Tong Zhang' 'Yilu Zhang' 'Xinxin Cui' 'Zhuo Li' 'Xiaomin Song' 'Kang Li' 'Mike Liu' 'Ye Liu'] Programmed cell death protein 1 (PD-1), an immune checkpoint receptor expressed by activated T, B, and NK cells, is a well-known target for cancer immunotherapy. Tislelizumab (BGB-A317) is an anti-PD-1 antibody…
Chen Li, Yi Ding, Shanshan Cai, Bai Cheng Liu + 1 more
Background Tislelizumab is an anti-programmed cell death protein 1(anti-PD-1) monoclonal antibody, which was approved by the Food and Drug Administration(FDA) on March 14, 2024. However, clinical studies are often limited by small sample sizes, and thus a more comprehensive evaluation of the safety of Tislelizumab…
Sha Jin, Zehu Liu, Fengming Zheng
Background Tislelizumab, a humanized IgG4 anti-programmed cell death 1 (PD-1) monoclonal antibody approved in China in 2019 for advanced solid tumors such as esophageal cancer, functions by blocking the PD-1/PD-L1 pathway to reactivate anti-tumor immunity. Common adverse reactions include fever and rash; however, toxic…
Man Yuan, Ning Han, Li Shu, Libo Yan + 1 more
The use of immune checkpoint inhibitors (ICIs) often develops immune-related adverse events (irAEs). However, irAEs-induced multi-organ injuries remain a rare event. We herein report a case of multi-organ injuries induced by tislelizumab in a lung squamous cell carcinoma (LUSC) patient. A 68-year-old man had undergone…
Hongtao Yu, Yunqian Li, Xifang Qu, Junkai Zhu + 2 more
Tislelizumab, a programmed cell death-1 inhibitor approved for multiple malignancies, may induce Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)-a rare but potentially fatal severe drug eruption-and early effective intervention is pivotal for reducing SJS/TEN-related mortality. We describe an elderly male…
Hiroki Hara, Taroh Satoh, Takashi Kojima, Takahiro Tsushima + 8 more
Background Esophageal squamous cell carcinoma (ESCC) has a poor prognosis, with limited second-line systemic therapy options, and represents an increasing disease burden in Japan. In the phase 3 RATIONALE-302 study, the anti-programmed cell death protein 1 antibody, tislelizumab, significantly improved overall survival…
Halie M. Rando, Nils Wellhausen, Soumita Ghosh, Alexandra Lee + 19 more
'Anna Ada Dattoli' 'Fengling Hu' 'James Brian Byrd' 'Diane N. Rafizadeh' 'Ronan Lordan' 'Yanjun Qi' 'Yuchen Sun' 'Christian Brueffer' 'Jeffrey Field' 'Marouen Ben Guebila' 'Nafisa M. Jadavji' 'Ashwin N. Skelly' 'Bharath Ramsundar' 'Jinhui Wang' 'Rishi R. Goel' 'YoSon Park' 'Simina M. Boca' 'Anthony Gitter' 'Casey S.…
Haitao Chen, Robert Bird, DaSheng Wang, Leilani Lotti Diaz + 5 more
CCovalent inhibitors are being used more frequently in drug discovery and is expected to revolutionize how enzyme inhibitors and receptor modulators are created in the future. More than 30 covalent therapies have been approved by the US FDA as a result of this approach, which has produced a wide spectrum of effective…
Qinli Sun, Masato Ogishi, Alison K. Barrett, Hua Jiang + 12 more
Depletion of pathogenic T and B cells is a pillar of therapies for autoimmune, inflammatory, and transplantation-related immunological diseases. However, adverse events, safety concerns in immunocompromised patients, and disease relapse limit clinical utility. Here, we exploit the immunosuppressive properties of a…
Shuowu Liu, Lizhu Sun, Chuqi Wang, Yingshu Cui + 8 more
The TIGIT (T cell immunoreceptor with Ig and ITIM domains) protein is a co-inhibitory receptor that has been reported to suppress autoreactive T and B cells to trigger immunological tolerance. We generated a new recombinant protein by connecting the extracellular domain of murine TIGIT to the Fc region of the rat…
Irene Shajan, Lea Rochet, Shannon Tracey, Rania Benazza + 7 more
Redirecting T cells to tumor cells by bispecific antibodies is an effective approach to treat cancer and T cell-dependent bispecific antibodies (TDBAs) are an emerging class of potent immunotherapeutic agents. By simultaneously targeting antigens on tumor cells and that on T cells, T cells are activated to kill tumor…
Jacob Du, Uthpala N. Wijayaratna, Xinyue Wang, Jeffrey P. Fung + 5 more
Acute myeloid leukemia (AML) is the most common acute leukemia in adults and is associated with poor outcomes due to frequent relapse after remission induction. While hematopoietic stem cell transplantation (HSCT) can improve survival, many individuals, especially older patients, are ineligible. Prior immunotherapies…